Holen Sie sich die Stockscreener-App
40.36
0.25%
0.10
Handel nachbörslich:
41.16
0.80
+1.98%
Schlusskurs vom Vortag:
$40.26
Offen:
$40.26
24-Stunden-Volumen:
4.91M
Relative Volume:
1.36
Marktkapitalisierung:
$17.24B
Einnahmen:
$2.31B
Nettoeinkommen (Verlust:
$1.66B
KGV:
17.57
EPS:
2.297
Netto-Cashflow:
$827.02M
1W Leistung:
-0.71%
1M Leistung:
+5.13%
6M Leistung:
+12.61%
1J Leistung:
+34.58%
1-Tages-Spanne:
$39.87
$40.49
1-Wochen-Bereich:
$39.87
$41.70
52-Wochen-Spanne:
$29.66
$41.70
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
40.36 | 17.20B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Will Royalty Pharma plc stock remain a Wall Street favoriteNew Guidance & Safe Entry Trade Signal Reports - moha.gov.vn
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Royalty pharma reports record year for royalty funding market By Investing.com - Investing.com Nigeria
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment - MSN
TEVA secures $500 million funding from Royalty Pharma for vitiligo drug - StreetInsider
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug - Benzinga
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - TradingView — Track All Markets
Royalty pharma reports record year for royalty funding market - Investing.com
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Royalty Pharma reports $4.7 billion in transactions for 2025 - StreetInsider
Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235 - Yahoo Finance
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Nigeria
Royalty Pharma provides up to $500 million for TEVA vitiligo drug - StreetInsider
Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment - Nasdaq
Royalty Pharma and Teva Enter $500 Million Funding Agreement for TEV-408 Development - Intellectia AI
Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development - Nasdaq
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation - GlobeNewswire Inc.
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo - The Manila Times
Teva and Royalty Pharma enter agreement to accelerate development of potential treatment for vitiligo - marketscreener.com
Drugmakers commit up to $500M to test a potential new vitiligo treatment - Stock Titan
A $500 million bet on a new vitiligo treatment aims to speed trials - Stock Titan
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Increases Dividend to $0.24 Per Share - MarketBeat
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi - MSN
Royalty Pharma’s Q3 2025 Earnings Call Highlights - MSN
Royalty Pharma raises quarterly dividend by 6.8% to $0.235/share - MSN
Royalty Pharma plc Declares Dividend on Class A Ordinary Share for the First Quarter of 2026, Payable on March 10, 2026 - MarketScreener
Royalty Pharma increases quarterly dividend by 6.8% to $0.235 - Investing.com India
Royalty Pharma shares edge higher on acquisition of oncology drug royalties - MSN
Royalty Pharma Increases Quarterly Dividend to $0.235 a Share From $0.22, Payable March 10 to Holders of Record on Feb. 20. - MarketScreener
Royalty Pharma Declares Q1 2026 Dividend of $0.235 per Share, Marking 6.8% Increase - Quiver Quantitative
Royalty Pharma Announces Dividend Increase - The Manila Times
Royalty Pharma plc (RPRX) Raises Quarterly Dividend 7.3% to $0.235; 2.3% Yield - StreetInsider
Moran Wealth Management LLC Increases Position in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock supported by strong cash flowsInflation Watch & Stock Timing and Entry Methods - ulpravda.ru
Is Royalty Pharma plc stock affected by interest rate hikesJuly 2025 Opening Moves & Growth Oriented Trade Recommendations - ulpravda.ru
Trade Report: How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Value Summary & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Is Royalty Pharma plc stock ready for breakoutJuly 2025 Technicals & Short-Term Swing Trade Alerts - ulpravda.ru
170,604 Shares in Royalty Pharma PLC $RPRX Bought by Hosking Partners LLP - MarketBeat
Royalty Pharma PLC $RPRX Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma stock hits 52-week high at $41.26 By Investing.com - Investing.com Nigeria
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX) - Barchart.com
Royalty Pharma stock hits 52-week high at $41.26 - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's Why - MarketBeat
United StatesGoodwin Guides Royalty Pharma On Acquisition Of Remaining Royalty Interest In Roche’s Evrysdi For $240 Million And Potential Milestones - Mondaq
Royalty Pharma plc (NASDAQ:RPRX) Nasdaq Index Life Sciences Partner - Kalkine Media
Generali Asset Management SPA SGR Grows Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Financiere des Professionnels Fonds d investissement inc. Invests $933,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones - citybiz
Why (RPRX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
What's Going On With Royalty Pharma Stock Wednesday?Royalty Pharma (NASDAQ:RPRX) - Benzinga
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Royalty Pharma Plc-Aktie (RPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Jan 02 '26 |
Sale |
38.42 |
69,582 |
2,673,041 |
39,760 |
| Urist Marshall | EVP, Research & Investments |
Jan 02 '26 |
Sale |
38.48 |
20,000 |
769,650 |
80,000 |
2.73%
2.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):